Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates.
Evan C ChenHelen GandlerIsidora TošićGeoffrey G FellAshlee FioreOlga PozdnyakovaDaniel J DeAngeloIlene GalinskyMarlise R LuskinMartha S WadleighEric S WinerRebecca LeonardKelsey O'DayAdrienne de JongeDonna S NeubergA Thomas LookRichard M StoneDavid A FrankJacqueline S GarciaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
We provide prospective, preliminary evidence that MET and FGFR are biologically active and safely targetable pathways in AML.